Gefitinib maintenance therapy versus gefitinib monotherapy in east asian never-smoker patients with locally advanced or metastatic nonsquamous non-small cell lung cancer: Final overall survival results from a randomized phase 3 study

Journal of Thoracic Oncology

Volumn 11, Issue 3, 2016, Pages 370-379

  Yang, James Chih Hsin ^a   Srimuninnimit, Vichien ^b   Ahn, Myung Ju ^c   Lin, Chia Chi ^a   Kim, Sang We ^d   Tsai, Chun Ming ^e   Mok, Tony ^f   Orlando, Mauro ^g   Puri, Tarun ^h   Wang, Xin ^h   Park, Keunchil ^c  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b MAHIDOL UNIVERSITY   (Thailand)

^c Sungkyunkwan University School of Medicine   (South Korea)

^d University of Ulsan College of Medicine   (South Korea)

^e NATIONAL YANG MING UNIVERSITY   (Taiwan)

^f CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^g Eli Lilly Interamérica Inc Suc Argentina   (Argentina)

^h ELI LILLY AND COMPANY   (United States)

Author keywords

East Asia; Gefitinib; Non small cell lung cancer; Overall survival; Pemetrexed

Indexed keywords

AFATINIB; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; PEMETREXED; ANTINEOPLASTIC AGENT; QUINAZOLINE DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; CANCER PATIENT; COMPARATIVE STUDY; CONFERENCE PAPER; CONTROLLED STUDY; DECREASED APPETITE; DIARRHEA; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EAST ASIAN; EGFR GENE; EXON; FEMALE; GENE DELETION; HUMAN; KAPLAN MEIER METHOD; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; NAUSEA; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); POINT MUTATION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RECEPTOR GENE; RETROSPECTIVE STUDY; SMOKING; VOMITING; WILD TYPE; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIAL; GENETICS; LUNG NEOPLASMS; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PEMETREXED; QUINAZOLINES;

EID: 84962549634     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1016/j.jtho.2015.11.008     Document Type: Conference Paper

References (31)

1. Cancer Research UK. Worldwide cancer mortality statistics. http: //www.cancerresearchuk.org/cancer-info/cancerstats/world/mortality/. Accessed May 25, 2015.
2. Saijo N, Fukuoka M, Thongprasert S, et al. Lung Cancer Working Group report. Jpn J Clin Oncol. 2010; 40(suppl 1): i7-i12.
3. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer. V.1.2015. www.nccn.org/professionals/physician-gls/PDF/nscl.pdf. May 25, 2015.
4. Azzoli CG, Baker S, Jr., Temin S, et al. American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol. 2009; 27: 6251-6266.
5. Socinski MA, Evans T, Gettinger S, et al. Treatment of stage IV non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013; 143: e341S-e368S.
6. Miller VA, Kris MG, Shah N, et al. Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J Clin Oncol. 2004; 22: 1103-1109.
7. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004; 304: 1497-1500.
8. Shigematsu H, Lin L, Takahashi T, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst. 2005; 97: 339-346.
9. Pan Q, Pao W, Ladanyi M. Rapid polymerase chain reaction-based detection of epidermal growth factor receptor gene mutations in lung adenocarcinomas. J Mol Diagn. 2005; 7: 396-403.
10. Riely GJ, Pao W, Pham D, et al. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin Cancer Res. 2006; 12: 839-844.
11. Yang JC, Kang JH, Mok T, et al. First-line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian patients with locally advanced or metastatic non-squamous non-small cell lung cancer: A randomised, phase 3 trial. Eur J Cancer. 2014; 50: 2219-2230.
12. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009; 361: 947-957.
13. Fleming ID, Cooper JS, Henson DE, et al., eds. AJCC Cancer Staging Manual. 5th ed. Philadelphia, PA: Lippincott-Raven Publishers; 1997.
14. Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest. 1997; 111: 1710-1717.
15. Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Control Clin Trials. 1996; 17: 343-346.
16. Fukuoka M, Wu YL, Thongprasert S, et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol. 2011; 29: 2866-2874.
17. Han JY, Park K, Kim SW, et al. First-SIGNAL: first-line single-Agent Iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. J Clin Oncol. 2012; 30: 1122-1128.
18. Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): An open label, randomised phase 3 trial. Lancet Oncol. 2010; 11: 121-128.
19. Yoshioka H, Mitsudomi T, Morita S, et al. Final overall survival results of WJTOG 3405, a randomized phase 3 trial comparing gefitinib (G) with cisplatin plus docetaxel (CD) as the first-line treatment for patients with non-small cell lung cancer (NSCLC) harboring mutations of the epidermal growth factor receptor (EGFR) [abstract 8117]. J Clin Oncol. 2014; 32(suppl): 5s.
20. Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010; 362: 2380-2388.
21. Inoue A, Kobayashi K, Maemondo M, et al. Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naive non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002). Ann Oncol. 2013; 24: 54-59.
22. Cheng Y, Murakami H, Yang P, et al. Randomized trial of gefitinib with and without pemetrexed as first-line therapy in East Asian patients with advanced NS NSCLC with EGFR mutations [ID 1319]. 16th World Conference on Lung Cancer, September 6-9, 2015; Denver, CO.
23. Yang JC, Wu YL, Schuler M, et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutationpositive lung adenocarcinoma (LUX-Lung 3 and LUXLung 6): Analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol. 2015; 16: 141-151.
24. Jackman DM, Yeap BY, Sequist LV, et al. Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. Clin Cancer Res. 2006; 12: 3908-3914.
25. Goto K, Nishio M, Yamamoto N, et al. A prospective, phase II, open-label study (JO22903) of first-line erlotinib in Japanese patients with epidermal growth factor receptor (EGFR) mutation-positive advanced non-small-cell lung cancer (NSCLC). Lung Cancer. 2013; 82: 109-114.
26. Jackman DM, Miller VA, Cioffredi LA, et al. Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-smallcell lung cancer patients: results of an online tumor registry of clinical trials. Clin Cancer Res. 2009; 15: 5267-5273.
27. Zhang Y, Sheng J, Kang S, et al. Patients with exon 19 deletion were associated with longer progression-free survival compared to those with L858R mutation after first-line EGFR-TKIs for advanced non-small cell lung cancer: A meta-Analysis. PLoS One. 2014; 9: e107161.
28. Mok TS, Wu Y, Nakagawa W, et al. Gefitinib/chemotherapy versus chemotherapy in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer after progression on first-line gefitinb: The phase III, randomized IMPRESS study [abstract LBA2PR]. European Society for Medical Oncology 2014 Congress. September 26-30, 2014; Madrid, Spain
29. Alimta (pemetrexed) [summary of product characteristics]. Indianapolis, IN: Eli Lilly and Company, 2014. http: //www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/000564/WC500025611.pdf. Accesed May 25, 2015.
30. Platinol (cisplatin) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company, 2010. http: //www. accessdata.fda.gov/drugsatfda-docs/label/2011/018057 s080lbl.pdf. Accessed May 25, 2015.
31. Iressa (gefitinib) [summary of product characteristics]. London, United Kingdom: AstraZeneca, 2014. http: //www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/001016/WC500036358. pdf. Accessed May 25, 2015.